BCBA/DHR (BCBA/DHR)

Buenos Aires Stock Exchange: BCBA/DHR · ARS

ARS 7,070

-120.07 (-1.7%)· Recorded snapshot

Market cap	251.1T
Revenue (ttm)	39T
Net income (ttm)	6.6T
EPS (ttm)	ARS 174
P/E (trailing)	40.7x
P/E (forward)	25.4x
Dividend	ARS 30.1 (0.43%)
Volume	638

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 39T
Net income (ttm): 6.6T
EPS (ttm): ARS 174
P/E (trailing): 40.7x
P/E (forward): 25.4x
Market cap: 251.1T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E25.4

P25 15P50 18.3P75 23.8

Trailing P/E40.7

P25 25.1P50 32.2P75 41.5

ROE8.2

P25 5P50 10.6P75 23.5

ROIC6.6

P25 7.2P50 13.5P75 19.8

Benchmarks · 1M

All BCBA/DHR indicators

Market & fundamental data

Available fields

230

Groups with data

Currency

USD

Showing 230 of 230 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	ARS
Country	United States
Country code	AR
Earnings date	2026-10-21
Employees	59,000
Employees change	-3,000
Employees growth	-4.76%
Enterprise value	ARS 285.1T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
Financial report date	2026-09-25
First seen	2026-05-10
Fiscal year end	December
Founded	1969
Industry	Diagnostics & Research
Is primary listing	No
ISIN number	AR0002457668
Last earnings date	2026-10-21
Last refreshed	2026-10-28
Market cap	ARS 251.1T
Price	ARS 7,070.00
Price currency	ARS
Sector	Healthcare
SIC code	3826
Stock price date	2026-10-27
Symbol	bcba/DHR
Website	https://www.danaher.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	34.56x
Average P/E ratio (3Y)	40.42x
Average P/E ratio (5Y)	36.35x
Earnings yield	2.46%
EV/Earnings	43.2x
EV/EBIT	32.94x
EV/EBITDA	21.59x
EV/FCF	32.67x
EV/Sales	7.24x
FCF / EV yield	3.06%
FCF yield	3.48%
Forward P/E	25.39x
Graham number	3101.55404
Graham upside	-56.13%
Lynch fair value	ARS 929.04
Lynch upside	-86.86%
P/(FCF - SBC) ratio	30.53x
P/(OCF - SBC) ratio	25.24x
P/B ratio	3.07x
P/E ratio	40.66x
P/FCF ratio	28.77x
P/OCF ratio	24.03x
P/S ratio	6.44x
Price/EBITDA ratio	19.96x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21.97%
EBITDA margin	32.24%
Effective tax rate	10.98%
FCF margin	22.15%
Gross margin	59.36%
Operating margin	21.97%
Pretax margin	18.81%
Profit margin	16.91%
Profit per employee	ARS 111.8M
Profitable quarters	98
Profitable years	33
Revenue per employee	ARS 661.3M
ROA	4.06%
ROA (5Y)	4.66%
ROCE	6.68%
ROE	8.19%
ROE (5Y)	9.78%
ROIC	6.6%
ROIC (5Y)	8.05%
SBC / revenue	1.28%
Tax / revenue	2.07%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	25.42%
EPS growth (Q)	37.77%
EPS growth (QoQ)	42.25%
EPS growth 10Y	5.5%
EPS growth 3Y	-8.35%
EPS growth 5Y	-4.99%
EPS growth quarters	5
EPS growth years	0
FCF growth	14.15%
FCF growth 3Y	-5.76%
FCF growth 5Y	-4.09%
Gross profit growth	5.11%
Gross profit growth (Q)	12.77%
Gross profit growth 3Y	6.93%
Gross profit growth 5Y	-2.4%
Net income growth	23.64%
Net income growth (Q)	36.01%
Net income growth (QoQ)	41.95%
Net income growth 3Y	-9.66%
Net income growth 5Y	-5.42%
Net income growth quarters	5
Net income growth years	0
OCF growth	8.56%
OCF growth 10Y	5.27%
OCF growth 3Y	-5.34%
OCF growth 5Y	-3.62%
Operating income growth	7.1%
Operating income growth (Q)	10.27%
Operating income growth 3Y	3.87%
Operating income growth 5Y	-6.08%
Revenue growth	5.52%
Revenue growth (Q)	8.28%
Revenue growth (QoQ)	4.61%
Revenue growth 10Y	4.42%
Revenue growth 3Y	6.79%
Revenue growth 5Y	-1.82%
Revenue growth quarters	6
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	ARS -1.7T
Depreciation and amortization	ARS 4T
EBIT	ARS 8.6T
EBITDA	ARS 12.6T
EPS	ARS 173.87
Financing cash flow	ARS 12.8T
Free cash flow	ARS 8.7T
Free cash flow minus SBC	ARS 8.2T
Gross profit	ARS 23.2T
Income taxes	ARS 805.9B
Investing cash flow	ARS -16.9T
Net borrowing	ARS 15.9T
Net cash flow	ARS 6.3T
Net income	ARS 6.6T
Operating cash flow minus SBC	ARS 9.9T
Operating income	ARS 8.6T
Revenue	ARS 39T
Stock-based compensation	ARS 501.2B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.47
Book value per share	ARS 116,138.18
Debt / EBITDA	3.24
Debt / equity	0.52
Debt / FCF	4.85
Goodwill	ARS 72.8T
Interest coverage	15.63
Long-term assets	ARS 119.4T
Long-term liabilities	ARS 46.5T
Net cash (debt)	ARS -33.7T
Net cash / market cap	-13.41%
Net debt / EBITDA	2.68
Net debt / equity	0.41
Net debt / FCF	3.86
Piotroski F-Score	5
Property, plant and equipment	ARS 10.7T
Shareholders' equity	ARS 81.7T
Tangible book value	ARS -22.5T
Tangible book value per share	ARS -31,938.48
Total assets	ARS 142.1T
Total cash	ARS 8.7T
Total debt	ARS 42.3T
Total liabilities	ARS 60.4T

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.3
Current assets	ARS 22.7T
Current liabilities	ARS 13.9T
Current ratio	1.63
Inventory turnover	3.58
Net working capital	ARS 3.3T
Quick ratio	1.19
Working capital	ARS 8.7T
Working capital turnover	8,651.47

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.6%
Dividend growth	79.85%
Dividend growth years	1
Dividend payment date	2026-10-30
Dividend payment years	3
Dividend payout frequency	Quarterly
Dividend per share	ARS 30.06
Dividend yield	0.43%
Ex-dividend date	2026-09-30
Last dividend	ARS 11.30
Payout ratio	23.46%
Shareholder yield	2.02%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	ARS 5,653.18
1D price change	-1.67%
1M price change	5.21%
1M total return	5.39%
1W price change	5.37%
1W total return	5.37%
1Y price change	8.69%
1Y return CAGR	9.24%
1Y total return	9.23%
20-day SMA	ARS 6,721.50
200-day SMA	ARS 5,741.26
3M price change	24.91%
3M total return	25.12%
50-day SMA	ARS 6,440.10
50-day SMA vs 200-day SMA	50over200
52-week high	ARS 7,260.00
52-week high date	2026-10-26
52-week low	ARS 4,430.00
52-week low date	2026-05-15
6M price change	42.9%
6M total return	43.32%
All-time high	ARS 13,700.00
All-time high date	2024-12-26
All-time low	ARS 3,400.00
All-time low date	2024-10-01
Average true range (ATR)	ARS 163.88
Average volume	3.8K
Change from 52-week high	-2.62%
Change from 52-week low	59.59%
Change from all-time high	-48.39%
Change from all-time low	107.94%
Change from open	-1.39%
Day's gap	-0.28%
Dollar volume	ARS 4.5M
High price	ARS 7,170.00
Low price	ARS 7,070.00
Monthly RSI	60.93
Open price	ARS 7,170.00
Position in 52-week range	0%
Previous close	ARS 7,190.00
Price vs 150-day SMA	25.06%
Price vs 20-day SMA	5.18%
Price vs 200-day SMA	23.14%
Price vs 50-day SMA	9.78%
Relative volume	0.17
RSI	62.5
Sharpe ratio	0.74
Sortino ratio	1.23
Volume	638
Weekly RSI	65.53
YTD price change	8.77%
YTD total return	9.23%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	626.3M
Shares change (QoQ)	-0.11%
Shares change (YoY)	-1.6%
Shares held by insiders	10.86%
Shares held by institutions	83.41%
Short ratio	1.9 days

Deeper analysis on BCBA/DHR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCBA/DHR report

Is a complete BCBA/DHR research report available?

No complete published report is available for bcba/DHR (BCBA/DHR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BCBA/DHR (BCBA/DHR)

Price

Financial snapshot

Fair-value bridge

Latest news · BCBA/DHR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCBA/DHR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCBA/DHR

Frequently asked questions